Home » Articles posted by administrator (Page 2)

Author Archives: administrator

Advanced Oncotherapy (AVO) – Additional Director Dealing

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that Dr Enrico Vanni, a Non-Executive Director of the Company, has today purchased 25,000 ordinary shares of 25 pence each in the Company at a price of 66 pence per Ordinary Share.

Following this transaction, Dr Vanni now holds 798,946 Ordinary Shares representing 1.1% of the issued share capital of the Company.

Advanced Oncotherapy Plc

www.avoplc.com

Dr. Michael Sinclair, Executive Chairman

Tel: +44 20 3617 8728

Nicolas Serandour, CEO

Stockdale Securities (Nomad & Joint Broker)

Antonio Bossi / David Coaten

Tel: +44 20 7601 6100

Stifel Nicolaus Europe (Joint Broker)

Jonathan Senior / Ben Maddison

Tel: +44 20 7710 7600

Walbrook PR (Financial PR & IR)

Tel: +44 20 7933 8780 or avo@walbrookpr.com

Paul McManus / Anna Dunphy

Mob: +44 7980 541 893 / Mob: +44 7876 741 001

About Advanced Oncotherapy Plc www.avoplc.com

Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy’s team “ADAM”, based in Geneva, focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates greater precision and electronic control which is not achievable with older technologies.

Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

Advanced Oncotherapy (AVO) – Significant Shareholder Dealing

Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that AB Segulah, a significant shareholder of the Company, today purchased 150,000 ordinary shares of 25 pence each in the Company at a price of 66 pence per Ordinary Share.

Following this transaction, AB Segulah now holds 3,219,451 Ordinary Shares representing 4.44% of the issued share capital of the Company.

Advanced Oncotherapy Plc

www.avoplc.com

Dr. Michael Sinclair, Executive Chairman

Tel: +44 20 3617 8728

Nicolas Serandour, CEO

Stockdale Securities (Nomad & Joint Broker)

Antonio Bossi / David Coaten

Tel: +44 20 7601 6100

Stifel Nicolaus Europe (Joint Broker)

Jonathan Senior / Ben Maddison

Tel: +44 20 7710 7600

Walbrook PR (Financial PR & IR)

Tel: +44 20 7933 8780 or avo@walbrookpr.com

Paul McManus / Anna Dunphy

Mob: +44 7980 541 893 / Mob: +44 7876 741 001

 

About Advanced Oncotherapy Plc www.avoplc.com

Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy’s team “ADAM”, based in Geneva, focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates greater precision and electronic control which is not achievable with older technologies.

Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

Buy Drax Power (DRX) says VectorVest. All the key factors are in place for continued growth

VVUKlogoDrax Group Plc (DRX.L) through its subsidiaries, engages in the generation and sale of electricity in the United Kingdom. Based in Selby, it owns and operates Drax Power Station, a coal-fired power station in North Yorkshire. This power station has an output capacity of 4,000 megawatts. The company also sells by-products of the electricity generation process, such as ash and gypsum; and levy exemption certificates, renewables obligation certificates, and sulphur dioxide emissions allowances. It sells electricity generated through the electricity wholesale market.

In the run up to preliminary results in February, on December 6th 2016, Drax published a trading update, and announced a conditional agreement to acquire Opus Energy Group Ltd and four Open Cycle Gas Turbine development projects. CEO Dorothy Thompson said the company continued to expect full year EBITDA to be around the bottom of the range of current market forecasts, but added that the Opus acquisition marked “an important step in delivering our strategy, contributing to stronger, more predictable, long-term, financial performance, through greater diversification of the businesses, delivering more opportunities right across the markets in which we operate.”

The investment opportunity at DRX had been flagged up by the VectorVest system as the stock started to drift lower around 280p during November 2016. The stock appeared on a number of metric indicators, including Relative Value (RV) and Relative Timing (RT) metric tables. RV is an indicator of long-term price appreciation potential, and DRX has an RV of 1.32, which is very good on a scale of 0.00 to 2.00. RT is a fast, smart, accurate indicator of a stock’s price trend that shows DRX RT rating at 1.63 – excellent on a scale of 0.00 to 2.00. Several other metrics highlighted the opportunity at DRX at the same time, with Value (the measure of a stock’s current worth) highlighting DRX at 452.49p per share, and therefore undervalued at its current Price of 366.80p per share.

A weekly chart of DRX is shown below with the share price graphed in candlestick format. Since December 2014 the share has been charting a large inverted head and shoulders reversal. This reversal was confirmed by a breakout of the “neckline” of the pattern in the last trading week. The target from the head and shoulders reversal should take the share towards the 500 level.

Many chartists would argue that the head of the reversal pattern is also a rounding bottom or cup formation. If so, then the handle of the cup and handle formation has given a strong buy signal in the last trading week as the 52 week high was exceeded.

Of note is the poor Relative Safety metric on VectorVest. At less than 1 this shows that there have been surprises and missed targets in the past. The opportunity looks good but solid and unemotional risk management should be in place and strictly adhered to.

In pursuing further diversification across its portfolio of businesses, DRX is clearly striking a chord with investors and major shareholders. Even though the stock now trades at year highs, the key VectorVest indicators show that all the key factors are in place for continued growth. Buy.

Dr David Paul

December 28th 2016

Readers can examine trading opportunities on DRX and a host of other similar stocks for a single payment of £5.95. This gives access to the VectorVest Risk Free 5-week trial, where members enjoy unlimited access to VectorVest UK & U.S., plus VectorVest University for on-demand strategies and training. Link here to view.

FREE! For free VectorVest analysis on any stock, go to this link here

VectorVest Unisearch

On VectorVest a simple search using the Unisearch tool will quickly find shares that are undervalued with good fundamentals that have just issued a Buy recommendation. This will give the active trader a short list of many high probability trading opportunities each week. Traders now have the opportunity to spend five weeks discovering VectorVest’s unique simplicity, automation and independent guidance. Just £5.95 buys a 5 week trial to enable deep exploration, or how the system can assist in smarter trading in as little as 10 minutes a day. Powerful tools. Proven strategies. Unique Perspectives.

Link here for more info and to set up a trial. 

European Financial Publishing Limited T/A VectorVest UK (VectorVest) is authorised and regulated by the Financial Conduct Authority under register number 543038. You should remember that the value of investments and the income derived therefrom may fall as well as rise and you may not get back the amount that you invest. Past performance is not a reliable guide to the future. This material is directed only at persons in the UK and is not an offer or invitation to buy or sell securities. If investors are in any doubt of the suitability of an investment given their individual circumstances, they are recommended to contact an investment manager or independent financial adviser who may be able to provide tailored advice. Opinions expressed whether in general or both on the performance of individual securities and in a wider economic context represent the views of VectorVest at the time of preparation. They are subject to change and should not be interpreted as investment advice. VectorVest and connected companies, clients, directors, employees and other associates, may have a position in any security, or related financial instrument, issued by a company or organisation mentioned on this site. European Financial Publishing Limited is a company incorporated in Scotland under Company Number SC357322 with its registered address at Exchange Tower, 19 Canning Street, Edinburgh EH3 8EH. Email: support@VectorVest.com

Dr Balaji Ganeshan speaks at International Conference on Artificial Intelligence in Healthcare – Feedback plc (FDBK)

Feedback (FDBK) – Dr Balaji Ganeshan speaks at International Conference on Artificial Intelligence in Healthcare. The conference is at the School of Pharmacy & Technology Management at NMIMS (www.nmims.edu) Shirpur Campus, India. More on the key speakers <a href="http://aihc.nmims this article.edu/key-speakers.php”>here

 

The Conference provides an interdisciplinary forum for research developers to present and discuss latest advances in research work as well as prototyped or fielded systems of applications of Artificial Intelligence in the wide and heterogeneous field of Medicine, Pharmacy, and Engineering in Health care. This conference will examine formalizations, methodologies and test benches for evaluating the numerous aspects of AI in health care. The conference also covers the whole range of theoretical and practical aspects, technology and system based on Artificial Intelligence in the Medical domain and aims to bring together specialists for exchanging ideas and promote fruitful discussions.

More info on the conference can be found here

Brand CEO Alan Green discusses Wincanton (WIN), Advanced Oncotherapy (AVO) and Andalas Energy (ADL).

Brand CEO Alan Green discusses Wincanton (WIN), Advanced Oncotherapy (AVO) and Andalas Energy (ADL) with Justin Waite on the VOX Markets podcast. Interview starts at 44 minutes 58 seconds.

Tertiary Minerals (TYM) – Publication of Report and Accounts & Notice of AGM

TYM1Tertiary Minerals plc, the AIM traded company building a strategic position in the fluorspar sector, is pleased to announce that the Annual Report for the year ending 30 September 2016, including the Notice of Annual General Meeting (“AGM”), is now available for download on the Company’s website www.tertiaryminerals.com and will be posted to shareholders today.

The AGM will be held on Tuesday 31 January 2017  at 2.30 p.m. at Arundel House, 13-15 Arundel Street, Temple Place, London  WC2R 3DX.

ENQUIRIES

Tertiary Minerals plc

Patrick Cheetham, Executive Chairman

Richard Clemmey, Managing Director

 

Tel: +44 (0)1625 838 679

S P Angel Corporate Finance LLP

Nominated Adviser & Joint Broker

Ewan Leggat/Lindsay Mair/Laura Harrison

 

Tel: +44 (0)203 470 0470

Beaufort Securities Limited

Joint Broker

Elliot Hance

 

Tel: +44 (0)207 382 8300

 

Brand Communications

Alan Green

 

Tel: +44 (0) 7976 431608

Notes to Editors

Tertiary Minerals plc (ticker symbol ‘TYM’) is an AIM-traded mineral exploration and development company building a significant strategic position in the fluorspar sector. Fluorspar is an essential raw material in the chemical, steel and aluminium industries. Tertiary controls two significant Scandinavian projects (Storuman in Sweden and Lassedalen in Norway) and a large deposit of strategic significance in Nevada, USA (MB Project).

CAUTIONARY NOTICE

The news release may contain certain statements and expressions of belief, expectation or opinion which are forward looking statements, and which relate, inter alia, to the Company’s proposed strategy, plans and objectives or to the expectations or intentions of the Company’s directors. Such forward looking statements involve known and unknown risks, uncertainties and other important factors beyond the control of the Company that could cause the actual performance or achievements of the Company to be materially different from such forward looking statements. Accordingly, you should not rely on any forward-looking statements and save as required by the AIM Rules for Companies or by law, the Company does not accept any obligation to disseminate any updates or revisions to such forward-looking statements

Advanced Oncotherapy (AVO) – Additional director dealing

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that Dr Enrico Vanni, a Non-Executive Director of the Company, purchased 25,000 ordinary shares of 25 pence each in the Company at a price of 59.75 pence per Ordinary Share.

Following this transaction, Dr Vanni now holds 773,946 Ordinary Shares representing 1.07% of the issued share capital of the Company.

Advanced Oncotherapy Plc

www.avoplc.com

Dr. Michael Sinclair, Executive Chairman

Tel: +44 20 3617 8728

Nicolas Serandour, CEO

Stockdale Securities (Nomad & Joint Broker)

Antonio Bossi / David Coaten

Tel: +44 20 7601 6100

Stifel Nicolaus Europe (Joint Broker)

Jonathan Senior / Ben Maddison

Tel: +44 20 7710 7600

Walbrook PR (Financial PR & IR)

Tel: +44 20 7933 8780 or avo@walbrookpr.com

Paul McManus / Anna Dunphy

Mob: +44 7980 541 893 / Mob: +44 7876 741 001

About Advanced Oncotherapy Plc www.avoplc.com

Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy’s team “ADAM”, based in Geneva, focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates greater precision and electronic control which is not achievable with older technologies.

Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

Tertiary Minerals (TYM) – Director Dealing

TYM1David Whitehead, Non-executive Director of the Company, is interested in 414,900 ordinary shares of 1 pence each in Tertiary.  These shares were held through Davycrest Nominees Limited, a nominee of Glebekinvara Management Services Limited.

GMSL is a company of which David Whitehead and his wife, Ann Whitehead, were both directors and in which they are both 50% beneficial shareholders.

GMSL is in the process of being liquidated (by way of a shareholders’ voluntary solvent liquidation) and on 19 December 2016, Davycrest transferred the 414,900 shares to GMSL.

Following this transfer of shares for no consideration, David Whitehead’s total interest in Ordinary Shares remains 414,900 Ordinary Shares.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details on the transfer of shares for no consideration by a director.

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

1.     

Details of the person discharging managerial responsibilities/person closely associated

a)

Name:

David Whitehead

2.     

Reason for the notification

a)

Position/status:

Non-executive Director

b)

Initial notification/Amendment:

Initial notification

3.     

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:

Tertiary Minerals plc

b)

LEI:

4.     

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument:

Identification code:

Ordinary shares of 1 pence each

 GB0008854563

b)

Nature of the transaction:

Transfer for no consideration

c)

Price(s) and volume(s):

 

Price(s)

Volume(s)

n/a

414,900

 

d)

Aggregated information:

Aggregated volume:

Price:

Single transaction as in 4 c) above

Price(s)

Volume(s)

n/a

414,900

 

e)

Date of the transaction:

2016-12-19

17.00hrs UTC

f)

Place of the transaction:

Outside a trading venue

Enquiries

Tertiary Minerals plc

Richard Clemmey, Managing Director

Patrick Cheetham, Executive Chairman

+44 (0) 1625 838 679

SP Angel Corporate Finance LLP

Nominated Adviser & Joint Broker

Ewan Leggat / Lindsay Mair

+44 (0) 20 3470 0470

Beaufort Securities Ltd

Joint Broker

Elliot Hance

+44 (0)20 7382 8300

Brand Communications

Alan Green

+44 (0)7976 431608

Notes to Editors

Tertiary Minerals plc (ticker symbol ‘TYM’) is an AIM-traded mineral exploration and development company building a significant strategic position in the fluorspar sector. Fluorspar is an essential raw material in the chemical, steel and aluminium industries. Tertiary controls two significant Scandinavian projects (Storuman in Sweden and Lassedalen in Norway) and a large deposit of strategic significance in Nevada, USA (MB Project).

CAUTIONARY NOTICE

The news release may contain certain statements and expressions of belief, expectation or opinion which are forward looking statements, and which relate, inter alia, to the Company’s proposed strategy, plans and objectives or to the expectations or intentions of the Company’s directors. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the control of the Company that could cause the actual performance or achievements of the Company to be materially different from such forward-looking statements. Accordingly, you should not rely on any forward-looking statements and save as required by the AIM Rules for Companies or by law, the Company does not accept any obligation to disseminate any updates or revisions to such forward-looking statements.

Advanced Oncotherapy (AVO) – Further progress in the technical development of the LIGHT system

AVO1Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that the Company has integrated the proton source and Radio Frequency Quadruple (RFQ), following a successful testing and calibration programme at ADAM, in Geneva.

This work has demonstrated there is a predicted acceleration of the proton beam through this very sophisticated structure, the RFQ, and that the measurements matched those expected from computer simulations. The completion of this key milestone is a significant indicator of the continued successful technical development of the Company’s LIGHT proton system.

Advanced Oncotherapy’s Professor Steve Myers, Executive Chairman of ADAM and previously Director of Accelerators and Technology at CERN and Head of CERN Medical Applications, stressed the significance of designing and building an RFQ with notably higher frequency and, hence, shorter wavelength and smaller dimensions than current comparable linear accelerators.

In the video recently made available on the Company’s website, Paul Collier, Head of Beams Department at CERN, spoke about the unique features of AVO’s LIGHT system’s RFQ, which has been designed and built by CERN:

“This high frequency RFQ is the most beautiful piece of equipment I have been involved in manufacturing. This is a very important piece of technology transfer from CERN to the outside world. We were challenged to design and build the world’s highest frequency and highest power RFQ.”

Advanced Oncotherapy Plc

www.avoplc.com

Dr. Michael Sinclair, Executive Chairman

Tel: +44 20 3617 8728

Nicolas Serandour, CEO

Stockdale Securities (Nomad & Joint Broker)

Antonio Bossi / David Coaten

Tel: +44 20 7601 6100

Stifel Nicolaus Europe (Joint Broker)

Jonathan Senior / Ben Maddison

Tel: +44 20 7710 7600

Walbrook PR (Financial PR & IR)

Tel: +44 20 7933 8780 or avo@walbrookpr.com

Paul McManus / Anna Dunphy

Mob: +44 7980 541 893 / Mob: +44 7876 741 001

About Advanced Oncotherapy Plc www.avoplc.com

Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy’s team “ADAM”, based in Geneva, focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates greater precision and electronic control which is not achievable with older technologies.

Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

Advanced Oncotherapy (AVO) – Additional Director Dealing

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that yesterday Dr Enrico Vanni, a Non-Executive Director of the Company, purchased a further 25,000 ordinary shares of 25 pence each in the Company at a price of 56 pence per Ordinary Share.

Following this transaction, Dr Vanni now holds 748,946 Ordinary Shares representing 1.03% of the issued share capital of the Company.

Advanced Oncotherapy Plc www.avoplc.com
Dr. Michael Sinclair, Executive Chairman Tel: +44 20 3617 8728
Nicolas Serandour, CEO
Stockdale Securities (Nomad & Joint Broker)
Antonio Bossi / David Coaten Tel: +44 20 7601 6100
Stifel Nicolaus Europe (Joint Broker)
Jonathan Senior / Ben Maddison Tel: +44 20 7710 7600
Walbrook PR (Financial PR & IR) Tel: +44 20 7933 8780 or avo@walbrookpr.com
Paul McManus / Anna Dunphy Mob: +44 7980 541 893 / Mob: +44 7876 741 001

 

About Advanced Oncotherapy Plc www.avoplc.com

Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy’s team “ADAM”, based in Geneva, focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates greater precision and electronic control which is not achievable with older technologies.

Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

I would like to receive Brand Communications updates and news...
Free Stock Updates & News
I agree to have my personal information transfered to MailChimp ( more information )
Join over 3.000 visitors who are receiving our newsletter and learn how to optimize your blog for search engines, find free traffic, and monetize your website.
We hate spam. Your email address will not be sold or shared with anyone else.